| | Business Summary | | CardioTech
International,
Inc.
is
using
its
proprietary
manufacturing
technology
to
develop
and
manufacture
small-bore
vascular
grafts,
or
synthetic
blood
vessels,
made
of
ChronoFlex,
a
family
of
polyurethanes
that
has
been
demonstrated
to
be
biocompatible
and
non-toxic.
Vascular
grafts
are
used
to
replace,
bypass
or
provide
a
new
lining
or
arterial
wall
for
occluded,
damaged,
dilated
or
severely
diseased
arteries.
The
Company
developed
a
vascular
access
graft
tradenamed
VascuLink
Vascular
Access
Graft
and
was
developing
a
peripheral
graft
tradenamed
MyoLink
Peripheral
Graft.
The
Company
sold
the
VascuLink
and
MyoLink
products
to
Nervation
Ltd
in
connection
with
the
disposition
of
its
United
Kingdom
subsidiary,
Cardiotech
International,
Ltd
(CTL).
The
Company
is
currently
developing
a
layered
microporous
coronary
artery
bypass
graft
tradenamed
CardioPass. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | CTE
uses
its
proprietary
technology
to
develop
and
manufacture
small
bore
vascular
grafts,
or
synthethic
blood
vessels,
made
of
ChronoFlex,
a
family
of
polyurethanes.
For
the
fiscal
year
ended
3/31/01,
revenues
rose
3%
to
$1.5
million.
Net
income
totalled
$5.7
million
vs.
a
loss
of
$3.8
million.
Revenues
reflect
increased
product
sales
of
biomaterials
and
an
increase
in
license
and
royalty
income.
Earnings
reflect
the
inclusion
of
a
$7.3
million
gain
on
the
sale
of
a
subsidiary. Recent Earnings Announcement
For
the
3
months
ended
06/30/2001,
revenues
were
817;
after
tax
earnings
were
-212. (Preliminary; reported in thousands of dollars.) | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Szycher, Ph.D., 62
Chairman,
CEO and Treasurer | $217K | David Volpe, 45
Acting
CFO | -- | Thomas Lovett, 45
Controller | -- | Michael Adams, 42
Clerk,
Director | 61K | | Dollar amounts are as of 31-Mar-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/c/cte.gif)